Unlabelled: Extracorporeal shockwave therapy showed a pronounced effect on bone mass in previous animal studies. We showed in this pilot study that a single treatment with unfocused shockwave therapy in unselected patients does not show side effects. Although our study did not show any effect of shockwave on BMD, the limited sample size does not definitively exclude this and a study with 174 subjects per group would be needed to show an effect size of 0.3 with a power of 80%.
Purpose: Unfocused extracorporeal shockwave therapy might stimulate bone formation to reduce the fracture risk. In this study, we assessed the safety of unfocused extracorporeal shockwave therapy and its effects on bone mass.
Methods: A clinical pilot study with twelve female patients free of bone disease undergoing elective surgery of the lower extremity or elective spinal surgery under general anesthesia received 3.000 electrohydraulic-generated unfocused extracorporeal shockwaves (energy flux density 0.3 mJ/mm) to one distal forearm. The contralateral forearm served as a control. We examined the effect on bone mass with the use of repeated dual energy X-ray absorptiometry measurements and we measured patient discomfort around the therapy.
Results: No difference in bone mineral content and density was measured 6 and 12 weeks after therapy. shockwave therapy occasionally caused transient erythema or mild hematoma, but no discomfort in daily life or (late) adverse events.
Conclusions: Unfocused extracorporeal shockwave therapy is a safe treatment, but no increase in bone mass on the forearm was found at 0.3 mJ/mm energy flux density. In this study, we were not able to demonstrate that a single treatment with unfocused shockwave therapy in unselected patients had any effect in terms of bone mineral density (BMD) or bone mineral content (BMC). A power analysis indicated that 174 patients per group are required to show an effect size of 0.3 with a power of 80%.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877705 | PMC |
http://dx.doi.org/10.1007/s11657-019-0650-x | DOI Listing |
J Chiropr Med
September 2024
Department of Health, Nutrition and Exercise Sciences, North Dakota State University, Fargo, North Dakota.
Objective: The purpose of this review was to evaluate the effectiveness of dry needling (DN) to improve function, proprioception, and balance and to reduce pain in individuals with chronic ankle instability (CAI).
Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for this review. We searched PubMed, ISI Web of Knowledge, Scopus, Science Direct, Google Scholar, and ProQuest databases from inception until July 2022 using the PICO (population, intervention, comparison, outcome) method.
Saudi Med J
January 2025
From the Physiotherapy Department (R. Alfaifi, Juraybi, Alrashed, Alghidani) Al-Rass General Hospital, Al-Rass; from the Neurosurgery Department (H. Alfaifi), Abha Maternity and Child Hospital, Abha, Kingdom of Saudi Arabia.
Objectives: To investigate the long-term effects of Extracorporeal shockwave therapy (ESWT) and ultrasound (US) in treating the trigger finger. Trigger finger, also known as stenosing tenosynovitis, is a common type of tenosynovitis affecting the flexor sheath of any finger. Extracorporeal shockwave therapy and therapeutic US are conservative treatments that use waves of varied frequency to target damaged regions and improve function.
View Article and Find Full Text PDFJ Sex Med
January 2025
Elexial Research Limited, Boston Medical, Department of Clinical Research, Mexico City 11000, Mexico.
Background: Shockwave therapy is an optional adjuvant treatment for vascular erectile dysfunction (ED). There is variability in treatment protocols and challenges with patients adherence to the weekly protocol, which is the most commonly used.
Aim: This study aimed to evaluate the noninferiority of a monthly shockwave therapy protocol compared to the weekly protocol for treating vascular ED.
J Am Coll Cardiol
January 2025
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: https://twitter.com/DLBHATTMD.
Background: In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease, most but not all randomized trials have reported that complete revascularization (CR) offers advantages over culprit vessel-only revascularization. In addition, the optimal timing and assessment methods for CR remain undetermined.
Objectives: The purpose of this study was to identify the optimal revascularization strategy in patients with STEMI and multivessel disease, using a network meta-analysis of randomized controlled trials.
Am J Cardiol
January 2025
Cardiology Division, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Baim Institute for Clinical Research, Boston, MA, USA. Electronic address:
There are limited tools available to predict the long-term prognosis of persons with coronary chronic total occlusions (CTO). A previously-described blood biomarker panel to predict cardiovascular (CV) events was evaluated in patients with CTO. From 1251 patients in the CASABLANCA study, 241 participants with a CTO were followed for an average of 4 years for occurrence of major adverse CV events (MACE, CV death, non-fatal myocardial infarction or stroke) and CV death/heart failure (HF) hospitalization.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!